BCLI · Brainstorm Cell Therapeutics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed May 15, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-24 | Pitts Peter Joe |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
900,000 |
| 2026-07-24 | FRENKEL JACOB A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting Person and the Issuer (the "Consulting Agreement") and subject to the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on October 24, 2026, and (ii) the remaining 50% of the award on April 24, 2027, provided that the Reporting Person continues to provide services to the Issuer pursuant to the Consulting Agreement through each applicable vesting date. |
Common Stock
|
100,000 |
| 2026-02-26 | Lebovits Chaim |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
1,800,000 |
| 2026-02-26 | Dagher Ibrahim B. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
225,000 |
| 2026-02-26 | Patlis Alla |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
100,000 |
| 2026-02-26 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-02-26 | Polverino Anthony J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-02-26 | Bairu Menghisteab |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-02-26 | Naor Nir |
CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
180,000 |
| 2026-02-26 | FRENKEL JACOB A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
200,000 |
| 2026-02-26 | ARBEL IRIT |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
120,000 |
| 2026-02-26 | Yablonka Uri |
Director, EVP & Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
150,000 |
| 2026-02-26 | HARTOUNIAN HARTOUN |
EVP, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Stock Option (Right to Buy)
|
225,000 |
| 2025-01-01 | Bairu Menghisteab |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
24,000 |
| 2025-01-01 | Dagher Ibrahim B. |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
50,000 |
| 2025-01-01 | HARTOUNIAN HARTOUN |
EVP, Chief Operating Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
50,000 |
| 2025-01-01 | Lebovits Chaim |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Common Stock
|
120,000 |
| 2025-01-01 | Yablonka Uri |
Director, EVP & Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan (the "Plan"). The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
40,000 |
| 2025-01-01 | ARBEL IRIT |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
30,666 |
| 2025-01-01 | Patlis Alla |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
40,000 |
| 2025-01-01 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
20,000 |
| 2025-01-01 | Yablonka Uri |
Director, EVP & Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
20,000 |
| 2025-01-01 | Naor Nir |
CFO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
30,666 |
| 2025-01-01 | FRENKEL JACOB A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
40,000 |
| 2025-01-01 | Polverino Anthony J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. |
Common Stock
|
24,000 |
| 2024-10-01 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.40 to $3.45, inclusive. |
Common Stock
|
1,836 |
| 2024-09-30 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.2258 to $0.2302, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. |
Common Stock
|
22,000 |
| 2024-07-19 | Dagher Ibrahim B. |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.3455 to $0.366, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote (1) to this Form 4. |
Common Stock
|
63,000 |
| 2024-06-24 | HARTOUNIAN HARTOUN |
EVP, Chief Operating Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of restricted stock units ("RSUs") awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date. |
Common Stock
|
30,000 |
| 2024-06-24 | HARTOUNIAN HARTOUN |
EVP, Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. |
Stock Option (Right to Buy)
|
60,000 |
| 2024-06-24 | HARTOUNIAN HARTOUN |
EVP, Chief Operating Officer |
Other↑
|
No Securities Owned
|
0 |
| 2024-05-28 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On June 3, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5161 to $0.5194, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. |
Common Stock
|
15,000 |
| 2024-05-22 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 23, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. |
Common Stock
|
25,000 |
| 2024-05-21 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 23, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. |
Common Stock
|
25,000 |
| 2024-05-13 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. |
Common Stock
|
10,000 |
| 2024-05-11 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. |
Common Stock
|
10,000 |
| 2024-05-10 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 14, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. |
Common Stock
|
20,000 |
| 2024-05-07 | Lebovits Chaim |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4. |
Common Stock
|
66,300 |
| 2024-05-07 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 7, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3738 to $0.3747, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. |
Common Stock
|
66,300 |
| 2024-05-06 | Lebovits Chaim |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.3498 to $0.399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4. |
Common Stock
|
135,000 |
| 2024-04-19 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On April 25, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. |
Common Stock
|
15,000 |
| 2024-04-18 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (3) to this Form 4. |
Common Stock
|
115,072 |
| 2024-04-17 | Lebovits Chaim |
President & CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4. |
Common Stock
|
130,000 |
| 2024-03-11 | Yablonka Uri |
Director, EVP & Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. |
Common Stock
|
109,426 |
| 2024-03-11 | Patlis Alla |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. |
Common Stock
|
65,246 |
| 2024-03-11 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. |
Common Stock
|
241,935 |
| 2024-03-11 | Lebovits Chaim |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. |
Common Stock
|
305,198 |
| 2023-09-01 | Lindborg Stacy |
Director, President and CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
11,500 |
| 2023-08-02 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of August 2, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. |
Common Stock
|
35,000 |
| 2023-08-02 | Lebovits Chaim |
President & CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of July 26, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. |
Common Stock
|
31,185 |